These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 19854437

  • 1. A combinatorial feature selection approach to describe the QSAR of dual site inhibitors of acetylcholinesterase.
    Asadabadi EB, Abdolmaleki P, Barkooie SM, Jahandideh S, Rezaei MA.
    Comput Biol Med; 2009 Dec; 39(12):1089-95. PubMed ID: 19854437
    [Abstract] [Full Text] [Related]

  • 2. Ensembles of Bayesian-regularized genetic neural networks for modeling of acetylcholinesterase inhibition by huprines.
    Fernández M, Caballero J.
    Chem Biol Drug Des; 2006 Oct; 68(4):201-12. PubMed ID: 17105484
    [Abstract] [Full Text] [Related]

  • 3. Efficient method for high-throughput virtual screening based on flexible docking: discovery of novel acetylcholinesterase inhibitors.
    Mizutani MY, Itai A.
    J Med Chem; 2004 Sep 23; 47(20):4818-28. PubMed ID: 15369385
    [Abstract] [Full Text] [Related]

  • 4. Receptor-dependent (RD) 3D-QSAR approach of a series of benzylpiperidine inhibitors of human acetylcholinesterase (HuAChE).
    Araújo JQ, de Brito MA, Hoelz LV, de Alencastro RB, Castro HC, Rodrigues CR, Albuquerque MG.
    Eur J Med Chem; 2011 Jan 23; 46(1):39-51. PubMed ID: 21074294
    [Abstract] [Full Text] [Related]

  • 5. Construction of the pharmacophore model of acetylcholinesterase inhibitor.
    Zhu Y, Tong XY, Zhao Y, Chen H, Jiang FC.
    Yao Xue Xue Bao; 2008 Mar 23; 43(3):267-76. PubMed ID: 18630262
    [Abstract] [Full Text] [Related]

  • 6. Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease.
    Muñoz-Ruiz P, Rubio L, García-Palomero E, Dorronsoro I, del Monte-Millán M, Valenzuela R, Usán P, de Austria C, Bartolini M, Andrisano V, Bidon-Chanal A, Orozco M, Luque FJ, Medina M, Martínez A.
    J Med Chem; 2005 Nov 17; 48(23):7223-33. PubMed ID: 16279781
    [Abstract] [Full Text] [Related]

  • 7. Discovery of dual binding site acetylcholinesterase inhibitors identified by pharmacophore modeling and sequential virtual screening techniques.
    Gupta S, Fallarero A, Järvinen P, Karlsson D, Johnson MS, Vuorela PM, Mohan CG.
    Bioorg Med Chem Lett; 2011 Feb 15; 21(4):1105-12. PubMed ID: 21273074
    [Abstract] [Full Text] [Related]

  • 8. Structural bioinformatics and QSAR analysis applied to the acetylcholinesterase and bispyridinium aldoximes.
    Mager PP, Weber A.
    Drug Des Discov; 2003 Feb 15; 18(4):127-50. PubMed ID: 15553925
    [Abstract] [Full Text] [Related]

  • 9. Ligand-based 3D-QSAR studies of physostigmine analogues as acetylcholinesterase inhibitors.
    Ul-Haq Z, Mahmood U, Jehangir B.
    Chem Biol Drug Des; 2009 Dec 15; 74(6):571-81. PubMed ID: 19843075
    [Abstract] [Full Text] [Related]

  • 10. In silico design and search for acetylcholinesterase inhibitors in Alzheimer's disease with a suitable pharmacokinetic profile and low toxicity.
    da Silva VB, de Andrade P, Kawano DF, Morais PA, de Almeida JR, Carvalho I, Taft CA, da Silva CH.
    Future Med Chem; 2011 Jun 15; 3(8):947-60. PubMed ID: 21707398
    [Abstract] [Full Text] [Related]

  • 11. An investigation of structurally diverse carbamates for acetylcholinesterase (AChE) inhibition using 3D-QSAR analysis.
    Roy KK, Dixit A, Saxena AK.
    J Mol Graph Model; 2008 Sep 15; 27(2):197-208. PubMed ID: 18515163
    [Abstract] [Full Text] [Related]

  • 12. Prediction of acetylcholinesterase inhibitors and characterization of correlative molecular descriptors by machine learning methods.
    Lv W, Xue Y.
    Eur J Med Chem; 2010 Mar 15; 45(3):1167-72. PubMed ID: 20053484
    [Abstract] [Full Text] [Related]

  • 13. Structural determinants of Torpedo californica acetylcholinesterase inhibition by the novel and orally active carbamate based anti-alzheimer drug ganstigmine (CHF-2819).
    Bartolucci C, Siotto M, Ghidini E, Amari G, Bolzoni PT, Racchi M, Villetti G, Delcanale M, Lamba D.
    J Med Chem; 2006 Aug 24; 49(17):5051-8. PubMed ID: 16913695
    [Abstract] [Full Text] [Related]

  • 14. Identification of molecular descriptors for design of novel Isoalloxazine derivatives as potential Acetylcholinesterase inhibitors against Alzheimer's disease.
    Gurung AB, Aguan K, Mitra S, Bhattacharjee A.
    J Biomol Struct Dyn; 2017 Jun 24; 35(8):1729-1742. PubMed ID: 27410776
    [Abstract] [Full Text] [Related]

  • 15. The MIA-QSAR method for the prediction of bioactivities of possible acetylcholinesterase inhibitors.
    Bitencourt M, Freitas MP, Rittner R.
    Arch Pharm (Weinheim); 2012 Sep 24; 345(9):723-8. PubMed ID: 22674790
    [Abstract] [Full Text] [Related]

  • 16. 3D QSAR studies of AChE inhibitors based on molecular docking scores and CoMFA.
    Akula N, Lecanu L, Greeson J, Papadopoulos V.
    Bioorg Med Chem Lett; 2006 Dec 15; 16(24):6277-80. PubMed ID: 17049234
    [Abstract] [Full Text] [Related]

  • 17. Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and beta-secretase.
    Zhu Y, Xiao K, Ma L, Xiong B, Fu Y, Yu H, Wang W, Wang X, Hu D, Peng H, Li J, Gong Q, Chai Q, Tang X, Zhang H, Li J, Shen J.
    Bioorg Med Chem; 2009 Feb 15; 17(4):1600-13. PubMed ID: 19162488
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A general method for exploiting QSAR models in lead optimization.
    Lewis RA.
    J Med Chem; 2005 Mar 10; 48(5):1638-48. PubMed ID: 15743205
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.